Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA336292
Max Phase: Preclinical
Molecular Formula: C14H22Cl2N5O12P3S
Molecular Weight: 648.25
Molecule Type: Small molecule
Associated Items:
ID: ALA336292
Max Phase: Preclinical
Molecular Formula: C14H22Cl2N5O12P3S
Molecular Weight: 648.25
Molecule Type: Small molecule
Associated Items:
Synonyms (1): AR-C67085
Synonyms from Alternative Forms(1):
Canonical SMILES: CCCSc1nc(N)c2ncn([C@@H]3O[C@H](COP(=O)(O)OP(=O)(O)C(Cl)(Cl)P(=O)(O)O)[C@@H](O)[C@H]3O)c2n1
Standard InChI: InChI=1S/C14H22Cl2N5O12P3S/c1-2-3-37-13-19-10(17)7-11(20-13)21(5-18-7)12-9(23)8(22)6(32-12)4-31-36(29,30)33-35(27,28)14(15,16)34(24,25)26/h5-6,8-9,12,22-23H,2-4H2,1H3,(H,27,28)(H,29,30)(H2,17,19,20)(H2,24,25,26)/t6-,8-,9-,12-/m1/s1
Standard InChI Key: ZLIAJZQKKBOFJR-WOUKDFQISA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 648.25 | Molecular Weight (Monoisotopic): 646.9576 | AlogP: 1.12 | #Rotatable Bonds: 11 |
Polar Surface Area: 269.90 | Molecular Species: ACID | HBA: 14 | HBD: 7 |
#RO5 Violations: 3 | HBA (Lipinski): 17 | HBD (Lipinski): 8 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 0.79 | CX Basic pKa: 5.12 | CX LogP: -1.85 | CX LogD: -6.50 |
Aromatic Rings: 2 | Heavy Atoms: 37 | QED Weighted: 0.08 | Np Likeness Score: 0.44 |
1. Ingall AH, Dixon J, Bailey A, Coombs ME, Cox D, McInally JI, Hunt SF, Kindon ND, Teobald BJ, Willis PA, Humphries RG, Leff P, Clegg JA, Smith JA, Tomlinson W.. (1999) Antagonists of the platelet P2T receptor: a novel approach to antithrombotic therapy., 42 (2): [PMID:9925726] [10.1021/jm981072s] |
2. Jacobson KA, Jarvis MF, Williams M.. (2002) Purine and pyrimidine (P2) receptors as drug targets., 45 (19): [PMID:12213051] [10.1021/jm020046y] |
3. Zetterberg F, Svensson P.. (2016) State of affairs: Design and structure-activity relationships of reversible P2Y12 receptor antagonists., 26 (12): [PMID:27133596] [10.1016/j.bmcl.2016.04.030] |
4. Warner DJ, Chen H, Cantin LD, Kenna JG, Stahl S, Walker CL, Noeske T.. (2012) Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification., 40 (12): [PMID:22961681] [10.1124/dmd.112.047068] |
Source(1):